Evidence mapPaperPMID 42467809Full record

ReviewTopics in antiviral medicine2026

Attention-deficit/hyperactivity disorder, autism spectrum disorder, and HIV: implications for risk, outcomes, and care for neurodivergent people.

Heather M Relyea Ashley, Sara K Stuart, Ellen F Eaton

Abstract readReview
In one paragraph

Review in Topics in antiviral medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Heather M Relyea AshleyUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Sara K StuartUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Ellen F EatonUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodivergence, including autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), is increasingly recognized as an important factor influencing health across the lifespan. Although ASD and ADHD are diagnosed categorically using standardized criteria based on the Diagnostic and Statistical Manual of Mental Disorders, the traits that define these conditions exist dimensionally across the population and are expressed with wide variability in support needs. Global ASD prevalence is approximately 1% to 2%, and emerging data suggest higher rates of autistic traits among some populations affected by HIV; however, estimates vary substantially based on methodology and diagnostic approach. ADHD affects approximately 2.5% of adults worldwide, although adult prevalence in people with HIV is not well characterized and likely underrecognized. Neurodevelopmental differences in executive function, reward processing, sensory regulation, and social communication may influence HIV acquisition risk, engagement in care, and long-term outcomes. Health care systems designed primarily for neurotypical individuals may inadvertently create barriers for neurodivergent patients. This review outlines a conceptual framework for understanding neurodivergence in the context of HIV, summarizes available epidemiologic and outcomes data, and provides practical strategies for delivering neurodiversity- affirming, accessible care.

Indexed as

Attention Deficit Disorder with HyperactivityAutism Spectrum DisorderHIV InfectionsHumansPrevalence

Identifiers

PMID42467809
PMCPMC13422892

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.